A detailed history of Credit Suisse Ag transactions in 89bio, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 60,103 shares of ETNB stock, worth $500,657. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,103
Previous 56,835 5.75%
Holding current value
$500,657
Previous $634,000 10.25%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$8.13 - $13.77 $26,568 - $45,000
3,268 Added 5.75%
60,103 $699,000
Q4 2023

Feb 08, 2024

BUY
$6.66 - $16.03 $45,780 - $110,190
6,874 Added 13.76%
56,835 $634,000
Q3 2023

Nov 13, 2023

SELL
$15.06 - $19.41 $286,998 - $369,896
-19,057 Reduced 27.61%
49,961 $771,000
Q2 2023

Aug 11, 2023

BUY
$14.15 - $22.03 $976,604 - $1.52 Million
69,018 New
69,018 $1.31 Million
Q2 2022

Aug 12, 2022

BUY
$2.09 - $4.02 $10 - $20
5 New
5 $0

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $387M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.